WFM
ANIK icon

Wilmington Funds Management’s Anika Therapeutics ANIK Stock Holding History

Wilmington Funds Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$296K Sell
6,385
-1,960
-23% -$87.2K 0.03% 532
2014
Q1 		$343K Sell
8,345
-2,709
-25% -$101K 0.04% 472
2013
Q4 		$422K Sell
11,054
-2,406
-18% -$74.2K 0.04% 445
2013
Q3 		$323K Buy
+13,460
New +$302K 0.03% 535

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

Wilmington Funds Management's ANIK Position: Q2 2014 in Review

Wilmington Funds Management reduced its Anika Therapeutics (ANIK) stake by 23% in Q2 2014, selling an estimated $87.2K and leaving 6,385 shares worth $296K. The position accounts for 0.03% of the portfolio, ranked #532.

Wilmington Funds Management first reported a position in ANIK in Q3 2013 and has held it in 4 quarters since. The position peaked at $422K in Q4 2013. 162 funds tracked by Wall St. Rank hold ANIK as of Q2 2014.

  • Wilmington Funds Management held 6,385 shares of Anika Therapeutics worth $296K as of Q2 2014.
  • Wilmington Funds Management sold 1,960 Anika Therapeutics shares in Q2 2014, an estimated $87.2K.
  • Anika Therapeutics made up 0.03% of Wilmington Funds Management's portfolio in Q2 2014, its #532 holding.
  • Wilmington Funds Management first reported a position in Anika Therapeutics in Q3 2013 and has held it in 4 quarters since.
  • Wilmington Funds Management's Anika Therapeutics position peaked at $422K in Q4 2013.
  • 162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.